Management of ocular manifestations of Behcet's disease: Outcome with cytotoxic drugs

APLAR Journal of Rheumatology

Volumn 8, Issue 2, 2005, Pages 119-123

  Davatchi, Fereydoun ^a   Shams, Hormoz ^a   Shahram, Farhad ^a   Nadji, Abdol Hadi ^a   Jamshidi, Ahmad Reza ^a   Akhlaghi, Ma'ssoomeh ^a   Abdollahi, Bahar Sadeghi ^a   Ziaie, Naghmeh ^a   Akbarian, Mahmood ^a   Gharibdoost, Farhad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Behcet's disease; Cytotoxic drugs; Oculo Behcet; Retinitis; Uveitis

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; METHOTREXATE; PREDNISOLONE;

ARTICLE; BEHCET DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETINA VASCULITIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 27844530317     PISSN: 02190494     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2005.00139.x     Document Type: Article

References (38)

1. Davatchi F (2004) New and innovative therapies for Behcet's Disease. APLAR J Rheumatol 7, 141-5.
2. Davatchi F, Baygan F, Chams H, Chams C (1984) Cyclophosphamide in the treatment of the ocular manifestations of Behcet's disease. J Rheumatol 11, 404-5.
3. Davatchi F, Chams H, Shahram F, Akbarian M, Hatef MR, Chams C (1988) Pulse cyclophosphamide in ophthalmologic manifestations of Behcet's Disease. In: Ferraz de Oliveira LN, ed. Ophthalmology Today. Amsterdam, Excerpta Medica, S.O.I. International Congress. Series 803, 387-91.
4. Davatchi F, Shahram F, Chams H et al. (1991) Pulse cyclophosphamide in ophthalmological manifestations of Behcet's disease. In: O'Duffy, JD, Kokmen, E, eds. Behcet's Disease Basic and Clinical Aspects. New York: Marcel Decker Inc, 555-61.
5. Fain O, Thi Huong Du L, Wechsler B et al (1991) Pulse cyclophosphamide in Behcet's Disease. In: O'Duffy, JD, Kokmen, E, eds. Behcet's Disease Basic and Clinical Aspects. New York: Marcel Decker Inc, 569-73.
6. Hamza M, Meddeb S, Mili I, Ouertani A (1992) Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet's disease. Preliminary results with the use of new criteria of evaluation. Ann Med Interne 143, 438-41.
7. Shahram F, Davatchi F, Chams H, Akbarian M, Gharibdoost F (1993) Low dose pulse cyclophosphamide (LDP) in ophthalmologic lesions of Behcet's Disease. In: Godeau, P, Wechsler, B, eds. Behcet's Disease. Amsterdam: Elsevier. Science Publisher, 683-6.
8. Davatchi F, Shahram F, Chams H et al (1998) Pulse cyclophosphamide for ocular manifestations of Behcet's Disease. Cohort study on 283 patients. Rev Rheum 65, 692.
9. Shahram F, Davatchi F, Chams H, Akbarian M, Chams C, Tebbi ME (1990) Methotrexate in ocular Behcet. Preliminary report. Disease. First APLAR Symposium on the Therapy of Rheumatic Diseases, Seoul, Korea, Abstract FP-23.
10. Davatchi F, Shahram F, Chams H et al (1998) Methotrexate for ocular lesions of Behcet's Disease. Cohort study on 262 patients. Arthritis Rheum 41, S356.
11. Shahram F, Davatchi F, Chams H, Akbarian M (1997) Cyclosporin in severe ocular lesions of Behcet's Disease. In: Hamza, M, ed. Behcet's Disease. Tunis: Publications Adhoua. 421-3.
12. Davatchi F, Shahram F, Chams H et al. (2000) Azathioprine for the treatment of ophthalmological lesions of Behcet's Disease. In: Bang, D, Lee, ES, Lee, S, eds. Behcet's Disease. Seoul Design Mecca Publishing Co, 898-900.
13. Davatchi F, Shahram F, Chams H et al (2003) High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv Exp Med Biol 528, 579-84.
14. Shahram F, Davatchi F, Chams H et al (2003) Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Behcet's disease. A preliminary report. Adv Exp Med Biol 528, 571-3.
15. Davatchi F (2000) Treatment of ocular manifestations of Behcet's disease. Proceedings, 9th Asia Pacific League of Associations for Rheumatology Congress. Beijing. China, 174-6.
16. Davatchi F (2002) Treatment of ocular manifestations of Behcet's Disease. Proceedings, 10th Asia Pacific League of Associations for Rheumatology Congress. Thailand, 28-32.
17. Davatchi F (2003) Treatment of ocular manifestations of Behcet's Disease. Adv Exp Med Biol 528, 487-91.
18. Shahram F, Davatchi F, Chams H, Akbarian M, Chams C (1992) Pulse Cyclophosphamide versus Pulse Methotrexate in Ophthalmological Manifestations of Behcet's Disease. In: Nasution AR, Darmawan J, Isbagio H (eds) APLAR Rheumatology. Tokyo: Churchill Livingstone, 119-22.
19. Shahram F, Davatchi F, Chams H, Akbarian Gharibdoost F (1993) Comparing 3 methods of Cytotoxic therapy in ophthalmologic lesions of Behcet's Disease. In: Godeau, P, Wechsler, B, eds. Behcet's Disease. Amsterdam: Elsevier. Science Publishers, 635-40.
20. Davatchi F, Shahram F, Gharibdoost F et al. (1996) Outcome analysis of ocular lesions in Behcet's Disease with 6 different therapeutic methods. Arthritis Rheum 39, S217.
21. Davatchi F (1998) Neuro-ophthalmic Behcet's. In: Torralba, TP, Amante, CM, Victorio-Navarra, STG, eds. APLAR 3rd. Symposium on the Therapy of Rheumatic Diseases. Hong Kong: Excerpta Medica Asia Ltd, 16-7.
22. Davatchi F, Shahram F, Chams H, Akbarian M (2004) Pulse cyclophosphamide in ocular manifestations of Behcet's Disease. A double blind crossover study. Arch Iranian Med 7, 201-5.
23. Davatchi F, Shahram F, Chams H et al. (2003) Cytotoxic drugs in ocular lesions of Behcet's Disease. Arthritis Res Ther 5, 3.
24. Ben Ezra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P (1991) Uveitis scoring system. Berlin Heidelberg: Sandoz Ltd and Springer Verlag.
25. Davatchi F, Shahram F, Chams H et al. (2003) The influence of the delay of aggressive treatment on the vision and its outcome in Behcet's disease. Adv Exp Med Biol 528, 493-4.
26. Wechsler B, Sablé-Fourtassou R et al. (2004) Infliximab in refractory panuveitis due to Behcet's disease. Clin Exp Rheumatol 22, S14-6.
27. Triolo G, Vadala M, Accardo-Palumbo A et al. (2002) Antitumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 61, 560-1.
28. Joseph A, Raj D, Dua HS, Powellt PT, Lanyon PC, Powelit RJ (2003) Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110, 1449-53.
29. Morris DS, Gavin MP, Sturrock RD (2003) The effect of antitumor necrosis alpha (Infliximab) on sight-threatening uveitis in a patient with Behcet's Disease. Adv Exp Med Rial 528, 557-9.
30. Sfikakis PP, Theodossiadis PG, Katsiari CG et al. (2001) Effect of Infliximab on sight threatening panuveitis in Behcet's Disease. Lancet 358, 295-6.
31. Katsiari CG, Theodissiadis PG, Kaklamanis PG, Markomichelakis NN, Sfikakis PP (2003) Successful long-term treatment of refractory Adamantiades-Behcet's Disease with Infliximab: Report of two patients. Adv Exp Med Rial 528, 551-5.
32. Behrens F, Zollner T, Moeller B, Kaltwasser JP, Kaufmann R, Ochsendorf F (2002) Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behcet's disease. Adv Exp Med Rial 528, 561-2.
33. Melikoglu M, Ozvazgan y Fresko I et al. (2002) The response of treatment resistant uveitis in Behcet's syndrome (BS) to a TNF-α blocker, Etanercept: an open study. Arthritis Rheum 46, S181, (Abstract) 400.
34. Tsambaos D, Eichelberg D, Goos M (1986) Behcet's syndrome treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 278, 335-6.
35. O'Duffy JD, Calamia K, Cohen S et al. (1998) Interferon-alpha treatment of Behcet's disease. Rheumatol 25, 1938-44.
36. Boyvat A, Sisman-Solak C, Curler A (2000) Long-term effects of Interferon alpha 2A treatment in Behcet's disease. Dermatology 201, 40-3.
37. Kotter I, Gunaydin I, Treush M, Zierhut M, Kanz L, Stubiger N (2003) The use of interferon-á in Behcet's Disease-Review of the literature and possible mechanisms of action. Adv Exp Med Biol 528, 503-9.
38. Kotter I, Zierhut M, Eckstein A et al. (2003) Human recombinant Interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet's disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 528, 521-3.